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Abstract
Clozapine is the drug of choice in treatment resistant schizophrenia. It reduces hospitalizations.
Patients on clozapine are often co-prescribed other psychotropics. This report looks at a sample
of twenty patients on clozapine. It finds that almost two thirds were on a psychotropic along with
clozapine. Eight individuals were on an antidepressant; seven on an antipsychotic and five were on
co-prescribed valproate. The clinical implications are discussed and a need to look at health
services involving clozapine is suggested.
Background
Clozapine, a novel antipsychotic due to its receptor bind-
ing profile, is the drug of choice in treatment resistant
schizophrenia (TRS). National Institute of Clinical Excel-
lence (NICE) recommends an early initiation of clozapine
therapy in individuals with TRS [1]. In UK, Clozapine is
licensed to be used for treating schizophrenia in patients
unresponsive to, or intolerant of, conventional antipsy-
chotic drugs [2].
The costs of clozapine therapy are high but these are
deemed to be cost effective, in view of the high levels of
morbidity and disability in the target population, and the
reduction of hospitalization [3-5].
Not much is known of the prescription of other psycho-
tropics when a patient is receiving clozapine. Do most
patients need only clozapine or do they still need co-pre-
scribed medications for treatment of emergent symptoms
or co morbid mental health problems? This report aims to
shed some light on the use of co-prescribed psychotropics
in a sample of patients receiving clozapine.
Method
Patients on clozapine, amongst the caseload of a consult-
ant psychiatrist (MG) were identified from the web site of
clozapine prescription monitoring system (CPMS). All
doctors who prescribe clozapine in England and patients
who receive clozapine are registered by CPMS. Regular
blood test results are received from CPMS. I used these test
results to cross check that I had the right number of
patients. All were being managed in the community.
In England, consultant psychiatrists or their deputed doc-
tors, write a letter to the general practitioner of the patient
they have seen, detailing their clinical observations, and
clinical plan. This is termed a clinical letter. The most
recent clinical letter from mental health services and the
most recent prescription from the surgery were obtained.
They were used as sources of information on the pre-
scribed medicines (Clozapine and others). Psychotropics
were identified (for the purpose of this report) as medica-
tion usually prescribed for the treatment of mental illness.
Thus benzodiazepines, procyclidine and hyoscine (the
latter two prescribed for alleviating side effects) were not
included as psychotropics. Psychotropics other than cloz-
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apine were identified and the dose recorded. This infor-
mation was tabulated.
Findings
Thirteen of twenty patients had co-prescribed psychotrop-
ics (65%). The most common co-prescription, in this
group of individuals, is of a serotonin specific reuptake
inhibitor (SSRI) (8/20). Antipsychotics were also co-pre-
scribed in 7 patients and 5 patients had been given val-
proate. None of the patients were on a co-prescribed
depot antipsychotic injection (Table 1).
Four patients were receiving concurrent procyclidine.
In all, 22 co-prescriptions were seen in these twenty indi-
viduals. There was no correlation with the dose of clozap-
ine.
Discussion
This short report shows that in a small sample of clozap-
ine treated patients, co-prescribed psychotropics are very
common. It is unfortunate that no published record of
such an observation could be found. A study of health
services involving clozapine will shed more light on this
topic.
Clozapine is known to reduce hospitalizations, though
this raises the cost of outpatient care and service utilisation
[5]. While a detailed cost estimation of patients on clozap-
ine needs to be undertaken, it has been suggested that con-
ventional antipsychotics have no disadvantage in terms of
symptoms and quality of life over a one-year period com-
pared to atypical antipsychotics [6]. On the other hand the
same appraisal suggested that clozapine was not signifi-
cantly at advantage in terms of quality of life when com-
pared to atypical antipsychotics. This report points to the
high use of co-prescriptions and thus the continued high
cost of health services for patients on clozapine.
Seven patients in this sample were receiving an antipsy-
chotic along with clozapine. Augmentation of clozapine is
a strategy with some support from open studies regarding
amisulpride [7,8] and aripiprazole [9]. Risperidone [10]
and sulpiride [11] have support from double blind rand-
omized placebo controlled studies. Indeed this study sam-
ple had four patients on amisulpride, two on risperidone
and one on sulpiride. One patient was however, on chlo-
rpromazine (along with amisulpride).
Clozapine is not known to cause extrapyramidal symp-
toms. It is suggested as an antipsychotic that eliminates
tardive dyskinesia. Procyclidine was co-prescribed in four
patients (one patient receiving both amisulpride and cloz-
apine) in this study sample. This is much higher than as
reported in a study from France [12].
Depression has been known to coexist with chronic phys-
ical illnesses. It has also been shown that about 25% of
Table 1: Clozapine and co-prescribed medication (psychotropics and procyclidine)
S. No. CLZ dose (mg) SSRI (name/mg) Antipsychotic (name/mg) VAL (mg) Others @ No. of Co-prescriptions
1. 600 - - - - 0
2. 300 - - - Pro 15 0
3. 250 - Ris 1 1500 - 2
4. 500 Flu 40 - 600 - 2
5. 200 Flu 20 Ami 150 - - 2
6. 450 - - - Pro 15 0
7. 850 - - 750 - 1
8. 600 Ser 100 Ris 2 - - 2
9. 500 - - - - 0
10. 800 Ser 100, Mir* - - Pro 15 2
11. 600 Cit 20 Ami 800 - Pro 10 2
12. 400 - - - - 0
13. 825 Ser 200 Ami 400, CPZ 100 - - 3
14. 350 Cit 20 Sul 800 - - 2
15. 400 - - - - 0
16. 500 - Ami 200 - - 1
17. 450 - - 900 - 1
18. 250 Par 20 - - - 1
19. 500 - - - - 0
20. 400 - - 400 - 1
CLZ = Clozapine; SSRI = Serotonin specific reuptake inhibitor; VAL = Valproate; Flu = Fluoxetine; Ser = Sertraline; Mir = Mirtazapine; Cit = 
Citalopram; Par = Paroxetine; Ris = Risperidone; Ami = Amisulpride; CPZ = Chlorpromazine; Sul = Sulpiride; Pro = Procyclidine;
* Mirtazapine is not a SSRI but is included in this column for clarity and grouping as an antidepressant.
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patients with schizophrenia will experience at least 1
depressive episode in their lifetime [13] – the suicide rate
of 10% holds true for the overall population of patients
with schizophrenia, whereas the suicide rate in those
without schizophrenia is 0.01% to 0.25% [14]. The use of
SSRI to treat or address depression might be a reason for
40% of this sample being co-prescribed antidepressants.
One study has found encouraging results involving
adjunctive SSRIs in treating the negative symptoms of
schizophrenia [15]. However, a review of controlled stud-
ies concluded that studies with positive findings have pri-
marily used fluoxetine or fluvoxamine [16,17] agents that
are notorious for increasing the plasma concentrations of
many antipsychotics. In contrast, the results of controlled
studies with sertraline and citalopram, which have fewer
propensities to cause interactions, have been negative
[18,19].
Thus co-prescription could be explained by the high mor-
bidity and mental health problems of the target popula-
tion. It would be interesting to study whether the adjuvant
medication is prescribed before clozapine started or after.
This report is limited in its extent of background informa-
tion and past history that could be elicited.
It is also food for thought as to whether clozapine is as
complete and effective a treatment as we think it is, if cli-
nicians do need to co prescribe a psychotropic. Is it treat-
ment resistant schizophrenia that we are treating or is it
co-morbid mental health difficulties that were not identi-
fied before clozapine was started.
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